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Background: Sporadic, inherited and acquired prion diseases show distinct histological patterns of abnormal prion
protein (PrP) deposits. Many of the inherited prion diseases show striking histological patterns, which often
associate with specific mutations. Most reports have focused on the pattern of PrP deposition in the cortical or
cerebellar grey matter.
Results: We observed that the subcortical white matter in inherited prion diseases frequently contained
filamentous depositions of abnormal PrP, and we have analysed by immunohistochemistry, immunofluorescence
and electron microscopy 35 cases of inherited prion disease seen at the UK National Prion Clinic. We report here
that filamentous PrP is abundantly deposited in myelinated fibres in inherited prion diseases, in particular in those
with N-terminal mutations.
Conclusions: It is possible that the presence of filamentous PrP is related to the pathogenesis of inherited forms,
which is different from those sporadic and acquired forms.
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proteinBackground
Human prion diseases represent a clinically and patho-
logically diverse group of neurodegenerative disorders
which invariably progress to a fatal outcome. Prion dis-
eases comprise sporadic forms (Creutzfeldt-Jakob disease
(sCJD)), inherited prion diseases (IPD) (sometimes also
classified as familial CJD (fCJD), Gerstmann-Sträussler-
Scheinker Syndrome (GSS) and fatal familial insomnia
(FFI)), and acquired forms with variant CJD (vCJD), iatro-
genic CJD and kuru. The common neuropathological
characteristics of human prion diseases are intraneuronal
vacuolation with neuronal loss (spongiform degeneration)* Correspondence: s.brandner@ucl.ac.uk
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reproduction in any medium, provided the orin the grey matter, reactive astrocytosis and microglia
activation as well as a highly variable accumulation of
abnormal prion protein (PrPSc), which represents
misfolded forms of normal cellular prion protein (PrPC).
The patterns of PrPSc deposition in prion diseases are well
characterised at immunohistochemical and ultrastructural
levels [1,2] and most observations focus on pathological
changes in the grey matter. Involvement of the cerebral
and cerebellar white matter in sCJD has been described
and suggested to be a primary or secondary process in
panencephalopathic type CJD [3,4]. Cerebellar white
matter PrP deposition is a prominent feature in the “VV2”
subtype type [5]. It also occasionally occurs in other forms
of prion diseases, where it is thought to be secondary to
cortical degeneration and neuronal loss. The presence of
PrP plaques in the white matter has been described in
various plaque-forming types of CJD including variant
CJD [6] and cases of sCJD with methionine homozygosityl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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series of 20 autopsy cases of CJD, white matter deposition
of abnormal PrP was examined in four cases by immuno-
histochemistry and transmission electron microscopy [8].
Abnormal PrP accumulation in the white matter is also
seen in sheep with atypical scrapie [9] as well as in scrapie-
infected Syrian hamsters where an intense white matter
PrPSc signal was seen in histoblot studies. This was thought
to support the hypothesis that PrPSc is transported along
axons [10].
Having observed conspicuous filamentous deposits of
abnormal PrP in the white matter in autopsy material
from patients with inherited prion disease attending the
National Prion Clinic and examined at autopsy between
2004 and 2012, we have subsequently analysed our cases
systematically for the presence of white matter PrP de-
posits. We distinguished the patterns of small granular
deposits or small plaques that are known for sCJD from
a fine, thread like pattern that was seen in inherited
cases. The present study describes the frequency, inten-
sity and incidence of this pattern in a series of 35 cases
of inherited prion diseases, comprising octapeptide re-
peat insertions (4OPRI, 5OPRI and 6OPRI) and PRNP
point mutations of the codons 102, 117, 178, 200 and
210. In addition we give a brief overview of the salient
PrP pathology that has been described previously in
these inherited forms [11]. We have deliberately omitted
a detailed description and discussion of other features
such spongiform degeneration, neuronal loss, gliosis,
and the glycotype patterns, as these have been exten-
sively reported elsewhere.
Methods
Research governance, post mortem examination and
tissue preparation
Ethical approval for these studies was obtained from the
Local Research Ethics Committee of UCL Institute of
Neurology/National Hospital for Neurology and Neurosur-
gery. Informed consent to use the tissue for research was
obtained. Clinical data, disease history, PRNP mutation
and PRNP codon 129 status were available for all cases.
Autopsies were carried out in a post mortem room desig-
nated for high risk autopsies. Brains were removed and
stored in buffered formalin. The frontal, temporal, parietal
and occipital cortex and the cerebellum were dissected
during the post mortem procedure and immersed in 10%
buffered formalin for up to one week, immersed into 98%
formic acid for one hour and postfixed for 24 h in 10%
buffered formalin. Tissues were then processed through
graded alcohols and embedded in paraffin wax. In a small
subset of cases, a small tissue block was prepared from the
frontal cortex and white matter and immersed into glutar-
aldehyde for preparation of semithin resin section and
electron microscopy. Frozen tissue of frontal brain andcerebellum was collected routinely and banked. The re-
maining brains were stored permanently in 10% formalin
and additional brain regions were dissected and processed
to paraffin blocks at later time points.
Antibodies and immunohistochemistry
In this study we used anti-PrP ICSM35 (D-Gen Ltd,
London, UK, raised in Prnpo/o mice against recombinant
human PrP as previously described [12];) and anti PrP
KG9 TSE Resource Centre, Roslin Institute University of
Edinburgh [13]. ICSM35 recognises residues 93–102 and
KG9 binds to residues 140–180 of human PrP. To detect
abnormal PrP deposition, mounted sections were treated
with 98% formic acid for 5 min, placed on an automated
Ventana Discovery staining machine, heated to 95°C in
2.1 mM Tris–HCl, 1.3 mM EDTA, 1.1 mM sodium cit-
rate, pH 7.8, for 30 min, digested for 16 min with a low
concentration of protease (Protease 3, 0.02 U/ml alkaline
protease, order no 760–2020 Ventana Medical Systems),
incubated in Superblock for 10 min, then exposed to the
primary antibody followed by biotinylated anti mouse IgG
secondary antibody and visualised using the iView detection
kit Haematoxylin was used as counterstain.
Immunofluorescence
Immunofluorescent dual labelling was carried out on se-
lected, representative frontal lobe sections of cases with
4OPRI, 6OPRI, P102L, A117V, D178N, E200K mutations
and sCJD 129MM, MV, and VV. For dual labelling and
co-localisation of abnormal PrP in white matter struc-
tures we applied the same antigen retrieval conditions as
above. Then we dispensed the antibody ICSM35 (1:1500)
together with either anti-Neurofilament (NF200, SIGMA
N5389; 1:100) or anti-Myelin Basic Protein (SMI94,
Covance, 1:250) followed by the secondary antibodies
labelled with fluorochromes Alexa 488 (goat anti Mouse
IgG1) or Alexa 546 (goat anti mouse IgG2b). Images were
taken on a ZEISS LSM510Meta Laser Scanning confocal
microscope, using a Plan-Apochromat 63×/1.4 Oil object-
ive. All images were taken at a scanning resolution that
matched the optical resolution of the lens (pixel size cor-
responding to 99.6 nm on the section).
Transmission electron microscopy
Tissue blocks of no more than 2 mm3 were immersed in
2.5% glutaraldehyde, treated with formic acid for 24 h
and following postfixation on glutaraldehyde, processed
for resin (Epon) embedding. Resin sections were stained
with Toluidine blue and suitable regions were selected
for electron microscopy. Ultra-thin sections were stained
with lead citrate and examined in a Jeol 100-CXII elec-
tron microscope. Images were recorded on a 4Megapixel
SIS Megaview digital camera.
Table 1 Description and definition of the quantification
of the filamentous or granular depositions
Score (granules or
threads)
Number of inclusions (High power field
(HPF) with a 40× objective)
0 Less than 1 inclusion per 4 HPF
1 More than 1 inclusion per 4 HPF, up to
5 inclusions per 1 HPF
2 5-20 inclusions per 1 HPF
3 More than 20 inclusions per 1 HPF
Scoring scheme used to semiquantitatively assess the frequency and density
of granular or filamentous inclusions in DAB stained paraffin sections on a
LEICA DM2500 with a 40× HCX Pan Apochromat objective.
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Brain tissue homogenates (10% w/v) from frozen samples
of frontal cortex were prepared in Dulbecco’s phosphate
buffered saline lacking Ca2+ or Mg2+ ions using tissue
grinders or by serial passage through needles of decreasing
diameter. Aliquots (typically 20 μl) were removed and
proteinase K added from a 1 mg/ml stock solution (pre-
pared in water) to give a final concentration in the sample
of 50 μg/ml. Following incubation at 37°C for 60 min,
samples were centrifuged at 16100 g for 1 min before
termination of the digestion by the addition of an equal
volume of 2 × SDS sample buffer (125 mM Tris–HCl,
pH 6.8, 20% v/v glycerol, 4% w/v sodium dodecyl sulphate,
4% v/v 2-mercaptoethanol, 0.02% w/v bromophenol blue)
containing 8 mM 4-(2-aminoethyl)-benzene sulfonyl
fluoride and immediate transfer to a 100°C heating block
for 10 min. Samples were centrifuged at 16100 g for
1 min prior to electrophoresis in 16% tris-glycine gels
(Invitrogen). Gels were electroblotted onto PVDF
membrane (Immobilon-P; Millipore) and subsequently
blocked in PBS containing 0.05% v/v Tween-20 (PBST)
and 5% non-fat milk powder for 60 min. After washing
in PBST, the membranes were incubated with anti-PrP
monoclonal antibody 3F4 (0.2 μg/ml in PBST) before
washing in PBST (60 min) and incubation with alkaline-
phosphatase-conjugated goat anti-mouse IgG secondary
antibody (Sigma-Aldrich Prod. No. A2179) diluted 1:10,
000 in PBST. After washing (1 h with PBST and 2 × 5 min
with 20 mM Tris pH 9.8 containing 1 mM MgCl2) blots
were incubated for 5 min in chemiluminescent substrate
(CDP-Star; Tropix Inc) and visualized on Biomax MR film
(Kodak). Control samples (of known PrPSc type) were
analysed in parallel and run on the same blots to enable
assignment of molecular strain type according to the
London classification [14,15].
Examination and quantification
We analysed 35 autopsy cases of inherited prion disease
seen at the National Prion Clinic, NHNN and these were
compared with 26 cases with sCJD (9 cases with codon
129 MM, 10 with MV and 7 with VV polymorphism).
The inherited cases included the following PRNP gene
mutations (numbers of cases in brackets): 4 octapeptide/
96 base pair repeat insertion [4OPRI] (3), 5OPRI/120 bp
(1), 6OPRI/144 bp (4), P102L (10), A117V (4), D178N
(3), E200K (9) and V210I (1).
Brains were examined in the following areas: Frontal,
temporal, parietal, occipital and cerebellar cortex. More
regions were available for some of the brains, sometimes
with very extensive sampling, but we restricted our
analysis to the above-mentioned representative areas of
subcortical white matter. Using a semi-quantitative scor-
ing scale (Table 1), all features were recorded for the
cortical areas and the cerebellum. Intensity and thedeposition pattern of PrP were recorded for the cortical
grey matter and the subcortical white matter, as well as
the cerebellar molecular and granular layers and the
cerebellar white matter. The following features were ob-
served and recorded: in the cortical grey matter, there
was synaptic labelling and deposition of plaques, in
addition filamentous PrP was present in the white mat-
ter fibres extending into the cortex. In the white matter,
we recorded small granules as well as thin threads of
variable length, which depended on the orientation of
the white matter tracts. The scores 0-3 reflect the abun-
dance of PrP deposits (threads or granules), which is
listed in Table 1. The quantity and the pattern of cortical
prion pathology was recorded for all cases as shown in
Table 2.
Statistical analysis
The quantity score of thread pathology was transformed
into numerical values (− = 0, + = 1, ++ =2, +++ =3.
4OPRI, 5OPRI and 6OPRI cases; and D178N, E200K,
V210I cases, were grouped together to allow group sizes
exceeding 3. The null hypothesis was the assumption of
no difference between groups. Table 3 shows the results
of the statistical analysis.
Results
35 cases of inherited prion disease were analysed, scored
for PrP staining patterns and compared with 26 cases of
sCJD. We observed changes in the grey and white mat-
ter that were similar to previously published patterns of
abnormal PrP deposition. The specific findings and indi-
vidual white matter staining pattern for each case with
mutations in the PRNP open reading frame, relevant
clinical data, codon 129 genotype, western blotting re-
sults, and cortical PrP pattern, are summarized in Table 2
and subsequently in this paragraph. In addition, a de-
tailed description of the findings is given below. PrPSc mo-
lecular strain typing analysis was performed for about half
the cases (Table 2). Where determined, molecular strain
types were consistent with those published previously [15]
however some brain samples were scored negative
for PrPSc (Table 2). The apparent absence of detectable
Table 2 List of all cases analysed for white matter PrP in this study













PrP p ttern WM Other pathology
T = hreads
D Dots
FB Cer FB Cer Cortical PrP pattern Spongiosis
1 V210L MV 2 M 69 5 + — T, D — S1, PN1, D2 +
2 E200K MM 2 M 65 4 + — D — S2, GR1, PN1 +
3 E200K MV ND M 67 24 + — D — S1 +
4 E200K MM ND F 57 6 ++ + D D S1, PN1 +
Figure 2D-F,
Figure 4A, B
5 E200K MV 2/3 F 45 38 +++ + T, D D S3, GR2 +++
6 E200K MM ND M 61 6 ++ + D D S2, GR2, PV2 +
7 E200K MM 2 M 65 5 — — — — S1, PN1 ++
8 E200K MM 2 M 65 9 + — D S1 +
9 E200K MM 2 F 69 4 + + D — S2, PN1 ++
10 E200K MM ND M 47 19 ++ ++ T, D T, D S2, D1, PV2 +
11 D178N MM Negative M 60 7 +++ + D D P3, D2 o
Figure 2A-C,
Figure 3I, J
12 D178N MV ND M 60 24 ++ — D — S2, GR1, P1 +++
13 D178N MV ND F 51 20 — — — — S1, GR1 ++
14 A117V MV Negative M 43 6 +++ ++ T D S2, P3, D3 o
15 A117V VV Negative M 40 46 +++ ++ T D S2, P3 ++
Figure 1M-P,
Figure 3G, H
16 A117V MV Negative M 47 47 +++ — T — S1, P3 o
Figure 5C, D 17 A117V MV ND F 40 98 +++ + T T, D S2, P3 ++
18 P102L MV Negative M 53 64 ++ ++ T T, D P3, D2 o
19 P102L MM 1 M 58 53 + + T D P3, D2 ++
20 P102L MM ND M 64 24 — + — T, D S1, P1 o
Figure 1I-L 21 P102L MM ND M 59 49 +++ +++ T, D T, D P3, D2 ++
22 P102L MV 2 F 64 33 +++ ++ D D S2, P3, D2 ++
23 P102L MV ND M 61 50 +++ +++ T, D T, D S2, P3, D1 +++
24 P102L MM 2 F 65 64 + ++ T, D T, D S1, P3, D2 ++
Figure 3E, F 25 P102L MM Negative F 62 48 ++ + D D S2, P3, D1, PV1 +
26 P102L MM Negative;8 kDa M 52 155 + + D D P2 o
27 P102L MM ND F 66 81 + +++ D T, D S1, P3 ++























Table 2 List of all cases analysed for white matter PrP in this study (Continued)
Figure 1E-H 29 6OPRI MV Negative F 46 0 +++ +++ T T, D S2, P3, D3 o
30 6OPRI MM ND M 44 118 +++ +++ T, D D S3, GR1, P1, D1 +
Figure 3C, D,
Figure 5A, B
31 6OPRI MM ND F 45 72 +++ ++ T T, D S1, PN1 +
32 5OPRI MM ND M 57 323 + + T, D T, D S1 +
33 4OPRI MM ND F 56 7 +++ + T T, D S3, GR1 +
Figure 1A-D,
Figure 3A, B
34 4OPRI MM ND M 73 14 ++ ++ T, D T, D S1 +++
35 4OPRI MM 2 F 62 5 ++ ++ T T, D S1, GR1, PN1 ++
*Proteinase K-digested PrP fragment size according to the London classification [14,15].
ND, not done.
All case numbers (first column) are cross-referenced to Figures 1, 2, 3, 4, 5 and 6. The columns on the right describe the pattern of PrP deposition in the white matter. The semi quantitative density scores of white
matter PrP are represented in column 8. mo: months, M: male/methionine, F: female, V: valine, WM: white matter, FB = Forebrain, Cer = Cerebellum, T = Threads, D = Dots. The two columns on the right describe the
pattern and intensity of cortical PrP deposition as described in [11] and the degree of spongiform changes. S = synaptic, PN = perineuronal net, GR = Granular; P = well demarcated plaques, D = diffuse plaques; and PV =


























1 (OPRI) 8 2.5 0.88
2 (P102L) 10 1.7 1.53
3 (A117V) 4 3 0
4 (E200K, D178N, V210I) 13 1.4446 0.7697
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some forms of inherited prion disease and in part relates
to sampling variation and in particular the region of brain
studied [15]. Typically we examined only a single sample
(~200 mg) of frontal cortex.
The white matter of brains with inherited CJD prion
disease show in the majority of cases filamentous PrP
deposition in the frontal, temporal parietal and occipital
regions of cerebral, subcortical white matter and to a
much lesser extent in the cerebellar white matter, and
the brain stem (Table 2, Figures 1, 2, 3, 4, 5, 6). Cortical
areas that contain significant amounts of abnormal
synaptic or plaque PrP, tend to show more abundant
filamentous white matter whilst a low cortical PrP load
is more often associated with very little or no filamen-
tous PrP in subjacent white matter tracts. Table 4 and
Figure 7 show the distribution of white matter filaments
in Case #17. In this case, the strongest labelling is seen
in frontal and temporal lobes, basal ganglia, followed by
parietal and occipital regions, and the least frequent
labelling in the cerebellum and pons. Occasionally we
found circular PrP deposits in cross sections (Figure 1Q),
suggestive of a localisation on myelin sheaths. In addition,
there was fine granular or dot-like positivity in almost all
cases, including sCJD of all three codon 129 genotypes
(MM, MV and VV). When the cases with filamentous
inclusions are plotted onto a diagrammatic representation
of the PRNP open reading frame, we observed that the
strongest and most consistent filamentous white matter
deposits were in cases with N-terminal mutations
(Figure 6), with octarepeat inserts, and A117V mutations,
followed by P102L mutations. These filaments were much
less frequent in brains with C terminal D178N, E200K and
V210I mutations. The intensity was unrelated to disease
duration or codon 129 genotype (Table 2) but appeared to
mirror cortical PrP load. The two groups with marked
formation of threads (4OPRI, 6OPRI and A117V) com-
prise younger patients (40-50ys); while patients with other
mutations were more than 50 years old with the exception
of two patients with an E200K mutation, of whom one
showed an unusual clinical phenotype with very long
disease duration (#5). The brain in this case showed fila-
mentous white matter PrP. One way ANOVA confirmed
that N terminal mutations are more likely to accumulate
filamentous abnormal PrP than the white matter of Cterminal mutant brains (Significance level p = 0.012). In-
stead, no filamentous, but variable granular PrP deposits
are seen in cases of sCJD, with no intensity difference
between the different polymorphisms on codon 129
(Table 5). Double labelling immunofluorescence studies
confirm the presence of PrP filamentous material in the
white matter. In keeping with light microscopy observa-
tions, the most abundant filaments are seen in 4- and
6OPRI, and A117V mutations, whilst P102L, D178N,
E200K and V210L mutations are less often associated with
filamentous PrP in the white matter. The filamentous
nature and the localisation at light microscopy level are
suggestive of axonal accumulation. To determine the pre-
cise location of the filaments in the white matter, we used
double–labelling immunofluorescence and detection by
confocal laser microscopy. There was virtually no overlap
between Alexa 488 labelled neurofilaments and Alexa 546
labelled PrP, suggesting that the filamentous deposits are
not in the axoplasm. Instead there were PrP threads that
appeared to flank and run in parallel to axons, suggesting
a localisation directly adjacent to the axoplasm of myelin-
ated fibres. Indeed further co-localisation studies with
Alexa 488 conjugated antibodies against myelin basic
protein confirmed that these filamentous PrP deposits
shows robust co-localisation of PrP threads with myelin
sheaths of all sizes. Longitudinal sections of myelinated
fibres occasionally contain PrP threads on either side of
the centrally located axons (Figure 3). Sections of dual
labelled axons show a co-localisation of PrP with MBP,
sparing the central axon (Figure 3). In contrast, samples of
sCJD contain granular deposits outside the myelin sheath
but no filamentous PrP (Figure 4), in keeping with the ob-
servations by light microscopy.
In the following paragraphs we describe PrP deposits
in cortical grey matter, followed by changes in the sub-
cortical white matter, cerebellar grey and white matter
changes and the co-localisation of abnormal PrP with
myelin and axonal structures. Finally, the results of the
dual labelling experiments are described. Type and inten-
sity of the white matter deposits (none, dot like/granular
or filamentous) with relation to the mutation are also
summarised in a graphic representation in Figure 7. This
figure also gives a reference to the cases in Table 2.
4OPRI [96 base pair insert] (1 male, 2 female); Figure 1A-D,
Figure 3A, B
The mean age for this group is 63.7 years (56–73)
(Cases #33-35). The cerebral grey matter of these cases
shows both axonal threads and granular synaptic stain
(Figure 1A). The white matter also shows threads and
dots of abnormal PrP (Figure 1B,C). The cerebellar
cortex displays the classical “striped” or “tigroid” pattern
of PrP depositions, perpendicular to the cerebellar sur-
face and the Purkinje cell layer as reported previously
Figure 1 (See legend on next page.)
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Figure 1 Threads of PrP positive deposits in inherited prion diseases with 4 and 6 octapeptide repeat insert mutation, P102L
(Gerstmann Sträussler-Scheinker syndrome), and A117V mutation. AD, 4OPRI mutation with abundant threads, which form a dense
crisscrossing network (corresponding to myelinated fibres) in the cortex (A) and forming multiple, thin parallel threads in the subcortical white
matter, detectable with two antibodies, ICSM35 (B) and KG9 (C). Arrowheads in B and C point to accentuated threads. In the cerebellum (D), the
PrP-containing filaments are thicker, shorter, and less abundant than in the cortex. The 6OPRI mutation (E-H) is characterised by abundant
threads in the cortical grey matter I, subcortical white matter (F, ICSM35, G, KG9), and in the cerebellar granular layer (H). I-L, Both forebrain and
cerebellum with PRNP P102L mutations show white matter threads of abnormal PrP in the subcortical (J, ICSM35 and K, KG9) or cerebellar (L)
white matter. Arrows I-L show short threads of PrP deposition. Small myelinated fibres extending into the cerebral cortex also show threads of
abnormal PrP (arrowhead in I) alongside with large amyloid plaques (not shown) and synaptic PrP. M-Q, A117V mutation (Case #16 M-P and Case
#17, Q) with abundant cortical threads (M), corresponding to myelinated cortical fibres. The inset shows several parallel threads. Also the
subcortical white matter is rich in PrP positive threads (N, ICSM35 and O, KG9). The cerebellum of the same case lacks filamentous inclusions,
whilst small granular deposits are often observed (P). The brain stem of case #17 shows cross sections of myelinated fibres with occasional
circular PrP-positive structures, corresponding to PrP containing myelin sheaths. Scale bar corresponds to 20 μm in P, 40 μm in the insets of E, F,
H and M, to 80 μm in C, G, H, O and to 140 μm in all other panels.
Figure 2 Patterns of PrP deposits in brains with PRNP D178N and E200K mutations. A-C, there are small dot like inclusions in the white
matter of a case with D178N mutation (A, B, ICSM35 and KG9), no cerebellar threads (C). D-F, E200K mutation with sparse threads in the
subcortical white matter (D, ICSM35 and E, KG9) and the cerebellar white matter (F). The inset in (D) shows a rare straight PrP positive filament
and the arrowhead points at a short stub or dot of abnormal PrP. The cerebellar white matter (F) of the same case shows occasional thicker,
straight filaments of abnormal PrP (arrowheads). Scale bar corresponds to 140 μm in (D), to 80 μm in B, E and to 40 μm in all other panels.
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Figure 3 Co-localisation studies of abnormal PrP (Alexa 546, red) with Neurofilament (A, C, E, G, I) or with myelin basic protein (B, D, F,
H, J), (green, Alexa 488) in the white matter of the frontal lobe. A, B, 4OPRI mutation shows the neurofilament signal being located beside
abnormal PrP (A, A’), whereas there is an overlap between MBP and PrP signal (B, B’). C, D; 6OPRI with filamentous PrP being localised next to
Neurofilament (C, C’) but directly congruent with MBP (D, D’). E, F there is little white matter PrP in this example of a P102L mutation, whilst a
case with an A117V mutation (G, H) shows abundant white matter PrP, which shows PrP immunoreactivity next to neurofilaments, (G, G’) and
co-localises with MBP, resulting in yellow signal (H, H’). The more C-terminal mutations, such as D178N show mostly granular PrP deposits and
no strong filamentous PrP (I, J). Scale bar 16μm for A-J and 4 μm respectively for A’-J’.
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ately frequent dots and thread-like staining (Figure 1D).
Filamentous deposits were seen with both antibodies
(Figure 1B, ICSM35 and 1C, KG9). All three 4OPRI cases
show consistent axonal labelling in cerebral grey andwhite matter as well as cerebellar white matter, in a pat-
tern and intensity similar to that observed in the 6OPRI
group [11,17]. Co-localisation studies (Figure 3A,B) with
PrP (red) and neurofilaments (green) show occasional
parallel course of PrP threads and axons (Figure 3A,A’),
Figure 4 Co-localisation studies of abnormal PrP (Alexa 546, red) with Neurofilament (A, C, E, G) or with myelin basic protein (B, D, F,
H), (green, Alexa 488) in the C-terminal E200K mutation and in sCJD control cases (frontal cortex). A, B, E200K mutations shows rare
filamentous PrP, co-localising with the myelin sheath (B, B’) but not detectably with axonal neurofilament (A, A’). All sCJD cases (129VV, C, D;
129MV, E, F; 129MM, G, H) show variable amounts of granular PrP which does not co-localise with neurofilaments (C, E, G) or Myelin basic
protein (D, F, H). Scale bar: 16 μm for A-H and 4 μm respectively for A’-H’.
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sheaths confirm the presence of the threads within the
myelin structure Figure 3B,B).5 OPRI [120 bp insert] (1 male)
The age of this patient was 57 years, with disease duration
of several years (Case #32). The onset of his illness was
difficult to determine as he gradually developed neuro-
logical symptoms in his forties which superimposed a
pre-existing personality disorder with aggressiveness and
outbursts. The brain showed PrP deposits that are similar
to sporadic sCJD and the characteristic striping pattern,
which is generally seen in the cerebellar cortex with
4OPRI and 6OPRI mutations, was absent. The cerebralwhite matter showed subtle white matter threads and
there was no white matter PrP in the cerebellum.
6OPRI [144 bp insert] (1 male, 3 female); Figure 1E-H,
Figure 3C,D, Figure 5A,B
The mean age for this group is 46 years (44–49) (cases
#28-31). In all cases the cerebral grey matter contains
abundant axonal threads (Figure 1E), as well as a granu-
lar synaptic stain and scattered microplaques. These
threads are present in the myelinated fibres that radiate
from the white matter into the cortex. The subcortical
white matter contains PrP positive threads (Figure 1F,
ICSM35 and 1G, KG9) and to a lesser extent, fine gran-
ules. The cerebellar molecular layer shows the classical,
distinct “stripy” or “tigroid” pattern with an orientation
Figure 5 Electron microscopy of two cases with abundant white matter deposition of PrP amyloid in the frontal cortex. A, B, Case #31
with 6OPRI mutation shows small granular deposits in the axoplasm of a longitudinal section of a myelinated axon, and more substantial fibrillar
electron dense deposits in a myelin sheath, that has become divided by these inclusions, raising the possibility of amyloid. C, D; Case #17 with an
A117V mutation shows a cross section of a myelinated fibre with the axon (Ax) being separated from the para-axonal inclusion that led to a
splitting of the myelin (My) sheath. The red box indicates the region shown in D with a characteristic electron dense deposition, raising the
possibility of amyloid. Scale Bars: 1 μm (A, C), 0.5 μm (B, D).
5OPRI 
6OPRI P102L A117V D178N E200K V210I 
White matter threads 
White matter dot like deposits 
No white matter deposits 
Point mutations 
OPRI (Octapeptide repeat insert) 















12 16 34 26 
7 





11 15 25 33 
4OPRI 
1 
Figure 6 Schematic representation of the deposition of white matter filamentous PrP in relation to the mutation: the horizontal bar
represents the PRNP open reading frame with the N terminus on the left and the C terminus on the right. OPRI and point mutations are
indicated with red symbols. At each mutation, the cases with white matter threads (filaments) are indicated with stars; the number of stars
indicates the abundance of deposits (corresponding to the score in Table 2). For cases where no filaments are seen, white matter dot-like
deposits are indicated by filled circles and cases with no white matter deposits are symbolised by open circles. The blue number next to the
symbols corresponds to the case numbers in Table 2, all figures and in the text). The position of the mutations on the schematic representation
is not exactly to scale.
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Table 4 Regional distribution of filamentous PrP in a
brain with A117V mutation (Case #17): semiquantitative
scoring of white matter PrP filaments
Case #17: areas analysed Density of filamentous PrP in
white matter tracts in the region
Anterior frontal F1-F2 +++
Posterior frontal Superior frontal










Basal ganglia, ant. +++
Basal ganglia, mid. +++









Cerebellum with dentate -
Cerebellum hemisphere (+)
The graphical representation is shown in Figure 7.
Figure 7 Regional distribution of filamentous PrP in a brain
with A117V mutation. (Case #17): the intensity of the white matter
filaments is represented in shades of red, the most intense
representing a strong deposition (frontal, parietal and temporal
brain) and there is a decreasing gradient towards the posterior
lobes, the cerebellum and the brain stem, where fewer filaments
were observed. The corresponding semi-quantitative evaluation is
listed in Table 6.
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before [11,18-20]. This pattern is a hallmark of octapep-
tide insert mutations and unlikely to be related to the
filamentous deposits. Threads are also seen in the cere-
bellar granule layer (Figure 1H) and the cerebellar white
matter shows variable amounts of dot- and thread-like
staining. Case #30 shows a staining pattern that varies
from the other cases with a 6OPRI mutation, in that the
grey matter displays granular synaptic positivity without
thread labelling and the white matter shows a predomin-
ance of granular labelling and fewer threads. In conclu-
sion, this group shows consistent, strong filamentous
positivity in both, grey and white matter (Figure 3), simi-
lar to the group with 4OPRI mutation (see above). The
cerebellar white matter shows thread pathology, a fea-
ture also seen in cases with P102L and 4OPRI muta-
tions. Co-localisation studies show a striking overlap of
PrP with myelin sheaths, whilst colocalisation with axons
was below detection limits, confirming that PrP threads
are located extra-axonal, within the sheath (Figure 3C,D).
However, ultrastructural studies of case #31 show granular
protein deposits also in the axoplasm but, in keeping with
immunofluorescence studies, more substantial deposits in
the myelin sheath, which appears displaced and split by
the amyloid aggregates (Figure 5A,B).
P102L (6 male, 4 female); Figure 1I-L, Figure 3E, F
The mean age for this group is 60.8 years (53–66) (cases
#18-27). The cerebral grey matter of these cases contains
frequent core- and multicentric plaques with diffuse
granular synaptic pattern as described before [21,22] and
occasional threads composed of abnormal PrP (Figure 1I).
The subcortical white matter contains scattered plaques of
small size with variable fine granular and thread-like posi-
tivity (Figure 1J, ICLM35 and 1K, KG9). The cerebellar
cortex shows plaques and large granular aggregates. The
white matter contains variable plaques, granules and short
threads (Figure 1L). In the majority of cases with P102L
mutation, a small, and at most moderate amount of fila-
mentous labelling can be observed in the white matter
and less dense axonal positivity in the grey matter. In
more than two thirds of the cases filamentous labelling is
also present in the cerebellar white matter. In immuno-
fluorescence studies however, nearly no filamentous ma-
terial was detected (Figure 3E,F).
A117V (3 male, 1 female); Figure 1M-P, Figure 3G,H,
Figure 5C,D
The mean age for this group is 43 years (40–47) (cases #14-
17). The grey matter contains frequent granular plaques
with diffuse, moderate-to-strong granular synaptic labelling
as well as strongly labelled short (Figure 2M inset) and long
filamentous white matter deposits (Figure 2M). In all three
cases the white matter shows frequent and intense thread-
Table 5 Summary of intensity scores in sporadic CJD
Scores for granular PrP (number of cases)
sCJD, codon 129 genotype Score 0 Score 1 Score2 Score 3 Significance
129MM 1 3 3 2 MM vs. MV: 0.23 (n.s.)
129MV 3 4 2 1 MV vs. VV: 0.72 (n.s.)
129VV 2 2 2 1 MM vs. VV: 0.48 (n.s.)
The left columns indicated the genotype of the codon 129 polymorphism, the subsequent columns the number of cases with the indicated scores (0–3) and the
right columns the statistical analysis of the scores between the different codon 129 genotypes. No statistically significant difference in the intensity scores are
seen between cases with codon 129 MM, MV or VV.
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(Figure 1N, ICLM35 and 2O, KG9). The cerebellar cortex
mainly contains patches of plaques and the white matter
shows occasional plaques with none or occasional dot-like
PrP deposits as described before [23,24]. In conclusion, this
group displays a strong, dense filamentous PrP labelling
in the cerebral white matter, similar to the 6OPRI and
4OPRI cases (see above), with significant filamentous PrP
extending to the myelinated axons in the cortical grey mat-
ter and no cerebellar threads. A cross section of the pons
(Figure 1Q) show occasional circular PrP deposits, strongly
suggestive of a localisation in the myelin sheath. Immuno-
fluorescent labelling confirms extensive co-localisation of
PrP threads in the sheaths of myelinated fibres, and no
axonal PrP. The dual labelling of PrP with neurofilaments
demonstrates no colocalisation of the signal (Figure 3G, G’),
whilst there is frequent and robust dual labelling of myelin
sheaths and filamentous PrP (Figure 3H, H’). All A117V
cases strongly accumulate filamentous PrP and it is gene-
rally very easy to detect filaments in the white matter of
A117V cases. Ultrastructural studies of case #17 show
substantial deposits of amyloid in the myelin sheath
(Figure 4C,D).
D178N (2 male, 1 female); Figure 2A-C, Figure 3I,J
The mean age for this group is 57 years (51–60); cases
#11-13. Both patients showed clinical CJD phenotype.
Here, the cortical grey matter shows diffuse, weak to mo-
derate fine granular synaptic stain with plaques of variable
size. The subcortical white matter shows a wide variability
(none to very frequent) of fine granular positivity but no
thread like labelling (Figure 2A, ICSM35 and 3B, KG9).
The cerebellar cortex shows patchy synaptic stain and granu-
lar aggregates with variable amounts of condensed granular
PrP, occasionally forming microplaques, and the subcortical
white matter has very rare or PrP dot-like positivity
(Figure 2C). Overall these cases show little PrP labelling
in the white matter and no thread-like PrP deposits. No
threads were detected by immunofluorescence, confirming
the observations by light microscopy (Figure 3I,J).
E200K (6 male, 3 female); Figure 2D-F, Figure 4A, B
The mean age for this group is 60 years (45–69) (cases #2-
10). The cortical grey matter shows diffuse, granular orfine dot-like synaptic staining that ranges from weak to
strong intensity, similar to that in sCJD. In addition, there
was cortical perineuronal PrP deposition with variable
amounts of microplaques, and there are rare filamentous
PrP deposits. The subcortical white matter contains vari-
able amounts (sparse to very frequent) of fine granular
positivity (Figure 2D) and occasional white matter threads
(Figure 2D, inset, ICSM35, and 2E, KG9). The cerebellar
cortex shows patchy synaptic staining and granular aggre-
gates with or without microplaques. The cerebellar white
matter shows rare granular positivity and threads in some
cases (Figure 2F). In one case (case 5 in Table 2) the cere-
bellar white matter showed frequent filamentous staining
as well as dot-like positivity (Figure 2F, Figure 4A,B). This
patient displayed an unusual clinical phenotype (younger
age and significantly longer disease duration) compared to
the other patients with the same mutation, which may
explain the difference to the patients with older age and
shorter disease duration. Overall, the PrP staining patterns
in brains with the E200K mutation are similar to those
observed in sCJD [25]. Among the cases with PRNP gene
mutations, this is the only group that shows perineuronal
PrP labelling. Double labelling immunofluorescence of
one case (#5) shows filamentous PrP deposits. There is
co-localisation of PrP in MBP positive myelin sheaths
whilst PrP in axonal structures is below the detection limit
(Figure 4A,B).
V210I (1 male)
In this single case (#1) with this mutation, the findings
are very similar to those in E200K mutations. We found
only cerebral PrPSc, some of which formed fine threads
but no cerebellar PrPSc. The cortex shows synaptic label-
ling with a homogenous distribution across all cortical
layers, similar to that of sCJD.
Sporadic CJD (26 cases), Figure 4C-H
26 cases with codon 129 polymorphism MM (9), MV (10)
and VV (7) were examined. All cases showed variable
amounts of granular PrP deposits, ranging from none to
frequent, corresponding to a score from 0–3 (see Tables
5 & 6). Across all cases, no difference was seen in the in-
tensities of granular white matter PrP deposition between
codon 129 genotypes MM, MV and VV. Double labelling
Table 6 List of sporadic CJD cases included in the control
group






PrP deposits in the frontal
subcortical white matter
(intensity score)
MM M 75 2.5 0
MM M 76 3 2
MM F 66 6 3
MM M 89 13 1
MM F 81 3 1
MM M 62 3 2
MM F 74 5 2
MM F 63 3 3






MV F 73 7 1
MV F 67 2 1
MV F 70 10 0
MV M 75 2 1
MV M 62 11 0
MV M 63 17 0
MV M 56 11 2
MV M 62 3 2
MV M 77 12 3






VV M 69 9 0
VV F 57 3 1
VV F 72 5 1
VV F 81 9 2
VV F 81 3 0
VV M 83 3 2






Cases with Codon 129MM, MV and VV alleles were used. The table also lists
the age at death, duration of illness and the density of granular PrP in the
white matter. The case numbers are cross-referenced in Figure 4.
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shows no co-localisation of granular white matter PrP
with either structure in all three codon 129 genotypes. In-
stead there is frequent granular PrP, which is immediately
adjacent to the myelinated fibres (Figure 4C-H).
Discussion
Our study shows that filamentous white matter PrP depos-
ition correlates with the localisation of the PRNP mutationand to some extent with the age of the patients. Previous
studies have described PrP plaques in the CNS white mat-
ter in various forms of prion diseases including vCJD [6]
and some cases of 129MM sCJD [7] and in the cerebellum
of 129VV patients [26]. A study of 20 autopsy cases of CJD
(not further specified), revealed PrPSc deposition in both
cerebral and cerebellar white matter in 4 cases [8]. Immu-
nohistochemical detection of abnormal PrP showed struc-
tures described as “arrays adjacent to ‘myelinic’ fibres and
as clumps adjacent to oligodendrocyte nuclei”, and trans-
mission electron microscopy showed that they were associ-
ated with “dense lysosomes in oligodendroglial perikarya
and in their processes”. These inclusions were charac-
terized as “finely fibrillary, paracrystalline, amorphous, or
densely osmophilic material”. The authors concluded that
white matter involvement in spongiform encephalopathy
may be due to direct modifications of oligodendroglial
cells associated with abnormal metabolism of PrP [8]. In
inherited prion diseases, white matter plaques have been
described before, and typically present as small, well
circumscribed amyloid deposits [21,24].
In animals, PrP accumulation in the white matter has
been described in sheep with atypical scrapie, with two
staining patterns; a ‘globular’ type, forming ring- or oval-
shaped deposits prominent in the spinocerebellar tracts, re-
ticular formation, cerebellar and cerebral white matter, and
other white matter tract areas and a ‘punctate’ type
consisting of small circle or elongated tear-drop deposits
prominent in several grey matter areas, e.g. the reticular
formation, substantia nigra, fimbria hippocampi, and amyg-
dala [9]. Again these features are distinct from the filament-
ous immunoreactivity in human inherited prion disease.
Experimental models of prion disease have added only little
insight into the possible pathogenesis of white matter PrP
deposition. In a study of scrapie infected Syrian hamsters
[10], an intense PrPSc signal was found in the white matter,
and was thought to support the hypothesis that PrPSc is
transported along axons, but the histoblot technique had a
resolution insufficient for the subcellular localisation of the
deposits. Studies using the mouse adapted Fujisaki prion
strain reported white matter destruction and deposition of
abnormal PrP in white matter tracts [8,27], without being
more specific regarding the PrP deposition pattern. The
CJD Fujisaki strain was derived from a brain that now is
regarded as a case of P102L GSS [27].
Several transgenic mouse models of inherited prion
disease have been generated but no specific white matter
pathology has been reported. A transgenic mouse model
expressing a nine-octapeptide insertion mutant mouse
PrP (9OPRI) fused with enhanced green fluorescent
protein [28] exhibited a striking white matter accumula-
tion of abnormal PrP with intra-axonal mutant PrP as
linear filamentous aggregates in central and peripheral
axons, suggesting disruption of axonal transport [28].
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no white matter PrP [29-34]. Transgenic mice expressing
a murine Prnp A116V (corresponding to the human
PRNP A117V) mutation [35] on a Prnp0/0 background
displays predominantly plaque pathology, chiefly in the
cerebellum. Mice expressing the homologue of the
human D178N (129V) mutation showed motor dysfunc-
tion, alteration of spatial working memory and abnormal
EEG pattern and sleep disturbances [36], histologically
punctate, micro-plaque like deposits, and ultrastructurally a
swelling of the endoplasmic reticulum of cerebellar granule
neurons. A model of the E200K mutation [34,37] showed no
spontaneous disease even after 900 days. Inoculation with
human E200K -129VV brain yielded extensive plaques while
an E200K 129MM inoculum yielded a predominantly synap-
tic pattern, but no white matter pathology was observed [34].
Previous studies of the transport of PrP along axonal
pathways in animal models have concluded that transport
of infectious prions uses mechanisms distinct from fast
axonal transport [38], in contrast to PrPC [39]. It has been
suggested that prion spread occurs via non-canonical
mechanisms [40,41], for example in a domino-like manner
along PrPC expressing nerve membranes or Schwann cells
[42]. It is possible that an impairment of axonal transport
or clearing mechanisms leads to deposition in the myelin
sheath of N-terminal mutant PrP. Whilst no quantitative
(and comparative) data exist for the amount of PrPC in
CNS oligodendrocytes and axons, experimental data of
the peripheral nervous system suggest that Schwann cells
express negligible levels of Prnp mRNA, and that expre-
ssion of axonal PrP is required for Schwann cell myelin
maintenance [43]. It is possible but remains speculative
that a similar mechanism, involving transfer of PrP from
the axon to the myelin sheath is relevant for the main-
tenance of CNS myelin. It is possible that soluble forms or
micro-aggregates of PrP, produced in the neuronal body,
move by passive or active axonal transport. Our ultrastruc-
tural studies provide evidence of granular protein deposits
in the axoplasm, possibly representing abnormal PrP, which
may eventually accumulate in myelin sheaths. Indirect
evidence for this suggestions comes from the observation
that the most abundant filamentous white matter PrP is
localised in the vicinity of cortical areas that contain signifi-
cant amounts of abnormal synaptic or plaque PrP, whilst a
low cortical PrP load is more often associated with very little
or no filamentous PrP in subjacent white matter tracts.
Filamentous PrP deposits are not observed in sCJD. A
possible explanation is the different pathogenesis, in that
all neuronal cells express mutant PrP and that all cells car-
rying the mutation may synchronously convert mutant
PrP into the abnormally folded form of PrP. The variabil-
ity between cases with the same mutation (see [22]) may
be explained by a variable capacity to clear abnormal PrP,
or a differential propagation of disease-related isoforms, asfor example shown for the P102L mutation, where at the
molecular level three isoforms of protease-resistant PrP
with divergent physicochemical properties can be propa-
gated [22]. The difference between cases with different
mutations can be explained by different propensities to
form deposits, as well as a region-specific propensity of
cell populations to accumulate abnormal PrP even within
the same family. It could also be argued that the initiation
of the disease as well as the mechanism of cell-to-cell
transmission in sporadic prion diseases is different from
inherited forms. A remarkable observation is a very strong
bivariate correlation between age of the patient at death
and the density of threads in the white matter (p = 0.001).
A regression model even favours age over mutation type,
that is, age is a stronger determinant of the density of
threads than the mutation itself (patients with more threads
die younger). However, this correlation is explained by the
fact that age at death correlates with the mutation.
Functional studies are required to further elucidate the
mechanism of PrP deposition in the myelin sheath, and
the propensity of N-terminal mutations to form such
inclusions.
Conclusion
We report here the presence of white matter deposition of
abnormal PrP in inherited prion diseases. Strikingly, abnor-
mal PrP appears to deposit in the myelin sheath of myelin-
ated axons. The filamentous inclusions are strongest in cases
with N-terminal mutations (OPRI, A117V) and less intense
or absent in mutations toward the C-terminus (D178N,
E200K). Areas that are most affected are in the frontal, tem-
poral and parietal lobes and less filaments are seen in the
occipital lobes, the cerebellum and the brain stem.
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